Welcome to our dedicated page for Equillium SEC filings (Ticker: EQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Equillium's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Equillium's regulatory disclosures and financial reporting.
Equillium, Inc. reports an estimated public float of $93.7 million, calculated from 47,085,662 shares held by non-affiliates and a per‑share price of $1.99. The $1.99 price was the highest closing price on The Nasdaq Capital Market within 60 days of this prospectus supplement's filing, specifically on September 11, 2025. The public float figure follows the method in General Instruction I.B.6 of Form S-3 under the Securities Act of 1933.
The company notes this figure is specific to the current filing and that if it later becomes subject to the limitations in General Instruction I.B.6, it will file another supplement to update the ATM prospectus. No other financial results, transactions, or forward-looking statements are provided in this excerpt.
Equillium, Inc. filed a Form S-8 registration statement to register additional shares of common stock for issuance under its 2018 Equity Incentive Plan and 2018 Employee Stock Purchase Plan. The filing relies on General Instruction E, which allows the company to increase the number of securities for existing employee benefit plans by incorporating prior effective S-8 registration statements by reference. The document also lists standard corporate and legal exhibits, including the company’s charter, bylaws, equity plans, legal opinions, auditor consent, and a filing fee table, and is signed by the chief executive officer and the full board of directors.
Equillium, Inc. filed an S-3 shelf registration to register common stock for resale by selling stockholders, including shares issuable upon exercise of pre-funded warrants sold in a recent private placement. The prospectus identifies multiple institutional holders (including Adage, ADAR1 Entities, Coastlands Capital and Janus) and shows specific share counts and warrants subject to beneficial ownership blockers that exclude certain exercisable shares from pre-offering ownership figures. The filing lists exhibits (e.g., merger agreement, charter documents, Registration Rights Agreement dated August 12, 2025 and pre-funded warrant form dated August 11, 2025) and incorporates prior SEC reports by reference. The total filing fee shown aggregates to $81,562.
Equillium, Inc. has regained compliance with Nasdaq’s minimum bid price requirement for its common stock. Nasdaq notified the company on August 29, 2025 that it once again meets Listing Rule 5550(a)(2) for continued inclusion on The Nasdaq Capital Market. Equillium had previously received notices in December 2024 and June 2025 that its shares were below the $1.00 per share bid price requirement, with an additional 180-day grace period granted in June. The company met the rule by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days, a condition that was satisfied on August 28, 2025.
Equillium, Inc. (EQ) reporting person Stephen Connelly, Chief Scientific Officer and Director, received an employee stock option award covering 1,025,000 shares on 08/29/2025 with an exercise price of $1.74. The filing shows the option as acquired (code A) and lists 1,025,000 shares beneficially owned following the transaction. The explanatory note states standard time-based vesting: 25% vest on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.
Tom Penny, Principal Accounting Officer and director at Equillium, Inc. (EQ), was granted an employee stock option on 08/29/2025. The option permits purchase of 525,000 shares of common stock at an exercise price of $1.74 per share and expires on 08/28/2035. Under the stated vesting schedule, 25% of the option vests on the first anniversary of the vesting commencement date and the remainder vests monthly over the following three years. The shares reported as beneficially owned following the grant are 525,000, held directly by the reporting person.
Equillium, Inc. (EQ) insider filing reports an equity award granted to Christine Zedelmayer, Sr. Vice President and COO. The Form 4 shows an employee stock option transaction dated 08/29/2025 for 725,000 options with an exercise price of $1.74. Following the grant, the filing reports 725,000 shares underlying the option as beneficially owned by the reporting person.
The filing includes a vesting schedule: 25% of the option shares vest on the first anniversary of the vesting commencement date, with the remainder vesting in 36 equal monthly installments thereafter. The option entry lists an associated date of 08/28/2035 in the table for exercisability/expiration fields as provided in the filing.
Bruce D. Steel, who is identified as President and CEO, Director and a 10% owner of Equillium, Inc. (EQ), reported a grant of an employee stock option on 08/29/2025. The option covers 1,695,000 shares of common stock at an exercise price of $1.74 per share and is exercisable through 08/28/2035. The report was signed on 09/02/2025.
The option vests with 25% vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. The filing indicates direct beneficial ownership of the underlying shares following the grant.
Equillium entered a Securities Purchase Agreement to sell 21,814,874 shares at $0.57 and pre-funded warrants to purchase up to 30,816,705 Warrant Shares at $0.5699, raising approximately $30.0 million at the anticipated Initial Closing. The agreement also permits a Milestone Closing to raise up to approximately $20.0 million if specified clinical or dosing milestones occur and a $2.50 VWAP price condition is met or waived by the investors.
Pre-funded warrants are exercisable at $0.0001 per share with net cashless exercise and beneficial ownership limits to restrict post-exercise holdings. The company agreed to file registration statements within 30 days of closings and faces cash penalties for registration failures. Equillium expects the net proceeds from the Initial Closing to extend its cash runway through 2027, is prioritizing development of EQ504, and has not initiated its announced cryptocurrency treasury reserve strategy.
Equillium, Inc. (EQ) filed an 8-K reporting an amendment to its Open Market Sale Agreement, preliminary cash of approximately $11.5 million as of June 30, 2025, and authorization of a cryptocurrency treasury reserve strategy.
The filing states that on August 3, 2025 the Company replaced Jefferies LLC with LifeSci Capital LLC as sales agent under its ATM Agreement (Amendment filed as Exhibit 10.1). On August 4, 2025 Equillium furnished a press release (Exhibit 99.1) disclosing preliminary, unaudited cash and a strategic expansion to integrate a cryptocurrency treasury reserve strategy; the Company has not purchased any cryptocurrency as of the filing. Equillium expects current cash to fund operations into the fourth quarter of 2025 based on certain assumptions and supplemented its risk factors relating to the crypto strategy (Exhibit 99.2).